E. David Crawford, MD, and Brian R. Hu, MD, presented “Nephron-Sparing Management of Low Grade UTUC with UGN-101 for Instillation-The OLYMPUS Trial.” for the Grand Rounds in Urology audience in August, 2019.

How to cite: Crawford, David E. and Hu, Brian R.. “Nephron-Sparing Management of Low Grade UTUC with UGN-101 for Instillation-The OLYMPUS Trial” August, 2019. Accessed Dec 2019. https://grandroundsinurology.com/nephron-sparing-management-of-low-grade-utuc-with-ugn-101-for-instillation-the-olympus-trial​/

Nephron-Sparing Management of Low Grade UTUC with UGN-101 for Instillation-The OLYMPUS Trial – Summary:

E. David Crawford, MD, and Brian R. Hu, MD, discuss the results of the use of UGN-101 to treat upper-tract urothelial cancer in the OLYMPUS trial, where it was shown to ablate low-grade tumors with a high initial complete response rate. They delve into the unique properties of UGN-101 and its successes and demonstrated side effects from the trial, as well as an upcoming study investigating a different formulation of the drug for treating bladder cancer.